



INTEGRATED INDUSTRIES LIMITED

CIN-L10719DL1995PLC277176

Formerly known as Integrated Technologies Limited

May 31, 2024

To,
The Manager (Listing Department)
BSE Limited
P.J Tower, Dalal Street,
Mumbai – 400 001
Scrip Code: 531889

Subject: Submission of Newspaper Clippings

Dear Sir/Madam,

Pursuant to Regulation 47 and other applicable regulations, if any of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed copies of the newspaper advertisement pertaining to financial results of the Company for the quarter and year ended on March 31, 2024. The advertisements were published in Pioneer, English and Pioneer, Hindi newspapers Today. The copy is enclosed herewith.

This is for your information and record.

Yours faithfully,

For Integrated Industries Limited
(formerly known as Integrated Technologies Limited)



Priyanka
Company Secretary and Compliance Officer

PRIYANKA

Digitally signed by
PRIYANKA
Date: 2024.05.31
11:33:48 +05'30'

NEW DELHI | FRIDAY | MAY 31, 2024

MODI ENDS LS POLL CAMPAIGN

PIONEER NEWS SERVICE ■

Prime Minister Narendra Modi ended his whirlwind Lok Sabha poll campaign with a rally in Punjab's Hoshiarpur on Thursday, closing out his electioneering the way he began — by focussing on a region where he has invested heavily over the years for the BJP to make a mark outside its strongholds. Modi notched up a total of 206 public-outreach programmes, including rallies and roadshows, since the Election Commission (EC) announced the poll schedule on March 16. The Prime Minister surpassed his nearly-145 public engagements on the stump during the 2019 polls by a big margin. The campaign period this time was of 76 days, compared to the 68 days in the polls held five years ago.

When the EC announced the polls, Modi was on a political tour of southern India, covering all five states in the three days between March 15 and March 17. The Bharatiya Janata Party (BJP) is eying to boost its fortunes in



Prime Minister Narendra Modi waves at crowd during a public meeting for Lok Sabha elections in Hoshiarpur, Punjab, on Thursday

BJP hails S&P ratings on India's growth

PIONEER NEWS SERVICE ■

NEW DELHI

The BJP on Thursday hailed the S&P Global Ratings' report on India's growth prospects as a "stamp of authority" on the success of the Centre's policies and hit out at opposition parties, saying they cannot see it as they are blindfolded.

After a gap of about 10 years,

S&P Global Ratings on Wednesday upped India's

outlook to positive from stable on robust growth prospects for the next three years and public spending, and raised hopes for an upgrade in two years, provided the Centre continues with its reforms and policies to keep fiscal deficit under check.

"It is a big achievement and a stamp of authority on the policies of Prime Minister Narendra Modi and the decisions taken for the country's progress now becoming visible."

"Our opposition parties cannot see it as they are blindfolded. Congress leader Rahul Gandhi and the leaders of other opposition parties are blindfolded, not the global agencies. They are clearly seeing the growth of the Indian economy. That is why they have upped India's outlook to positive," the BJP leader added.

He said global rating agencies



have started understanding Modi's resolve to make India a developed country with the results of his government's policy initiatives and decisions taken for the country's progress now becoming visible.

"We are fully confident that this time again, they will ensure the BJP's victory (in the Lok Sabha polls) with a thumping majority," Islam said.

The last phase of polling for the parliamentary election is scheduled to be held on June 1 for 57 constituencies spread across eight states, including Punjab, Uttar Pradesh and West Bengal. The counting of the votes cast in all the seven phases of the election will be taken up on June 4.

Emaar India Limited

 CIN - U45201DL200PLC13361
Registered Office: 306-308, Square One, C-2, District Centre, Saket, New Delhi – 110017
Email ID - bharat.garg@emaar.ae, Website - www.in.emaar.com

Audited Financial Results for the Quarter and Year Ended March 31, 2024 (Rs. in million)

S. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Quarter ended		Year ended	
		31-Mar-24 Audited	31-Mar-23 Audited	31-Mar-24 Audited	31-Mar-23 Audited	31-Mar-24 Unaudited	31-Mar-23 Unaudited	31-Mar-24 Audited	31-Mar-23 Audited
1	Total Income from Operations	2,463.40	4,360.56	27,565.67	17,657.62	3,490.11	4,479.40	29,137.73	18,318.99
2	Net profit/(loss) for the period/year (before Tax, Exceptional and/or Extraordinary items)	(3,680.02)	673.23	(2,385.20)	97.07	(1,823.78)	399.50	(1,306.07)	(76.74)
3	Net profit/(loss) for the period/year before tax (after Exceptional and/or Extraordinary items)	(3,680.02)	673.23	(2,385.20)	(1,186.78)	(1,823.78)	399.50	(1,306.07)	(1,360.59)
4	Net profit/(loss) for the period/year after tax (after Exceptional and/or Extraordinary items)	(3,680.02)	673.23	(2,385.20)	(1,186.78)	(1,829.62)	392.14	(1,340.84)	(1,408.38)
5	Total Comprehensive income/(loss) for the period/year [Comprising Profit / (Loss) for the period/year (after tax) and other Comprehensive Income (after tax)]	(3,686.68)	674.17	(2,382.86)	(1,178.98)	(1,829.54)	398.46	(1,338.72)	(1,454.34)
6	Paid up Equity Share Capital	1,693.87	1,693.87	1,693.87	1,693.87	1,693.87	1,693.87	1,693.87	1,693.87
7	Reserves (excluding Revaluation Reserve)	-	-	(39,951.20)	(37,568.33)	-	-	(35,432.54)	(34,141.89)
8	Net Worth	-	-	(38,257.33)	(35,136.33)	-	-	(33,738.67)	(32,448.02)
9	Paid up Debt Capital / Outstanding Debt	78,726.31	78,831.95	78,726.31	78,485.34	78,832.27	78,485.34	78,832.27	78,485.34
10	Outstanding Redeemable Preference Shares	-	-	-	-	-	-	-	-
11	Debt Equity Ratio	(2.10)	(2.06)	(2.05)	(2.06)	(2.30)	(2.28)	(2.30)	(2.28)
12	Earning / (Loss) Per Share (in Rupees) (Basic & Diluted)	(21.73)	3.97	(11.50)	(7.01)	(10.81)	2.32	(2.46)	(8.25)
13	Capital Redemption Reserve	-	-	-	-	-	-	-	-
14	Debenture Redemption Reserve	738.13	738.13	738.13	738.13	738.13	738.13	738.13	738.13
15	Debt Service Coverage Ratio	(0.38)	1.07	0.08	0.12	(0.01)	0.95	0.27	0.12
16	Interest Service Coverage Ratio	(1.11)	1.43	0.64	0.83	(0.04)	1.26	0.82	0.81

Notes:

1. The above is an extract of the detailed format of financial results filed with stock exchange under regulation 52 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015. The full formats of financial results are available on the website of the stock exchange www.bseindia.com and on the Company's website www.in.emaar.com.
2. For the other line items referred in regulation 52(4) of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015, pertinent disclosures have been made to the Stock Exchange and can be accessed on the website of stock exchange www.bseindia.com.
3. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on May 29, 2024.

For and on behalf of Board of Directors of Emaar India Limited

 Sd/-
Jamal Majed Khalfan Bin Theniyah
Director
DIN - 07534810

Date : May 29, 2024

Place : Gurugram

PARIJAT PAPER MILLS LIMITED

CIN: L21012UP1989PLC010589

Reg. Off: 10.6 Km Stone Bhopa Road, Vill-Jat Mujhera, Muzaffarnagar - 251308, (U.P)

Website: www.parijatpapermills.com, Email: parijsatpapermills@yahoo.com

EXTRACT OF STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31.03.2024 (Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended (Audited)	Quarter Ended (Audited)	Year Ended (Audited)
		31.03.2024	31.03.2023	31.03.2024
1.	Total income from operations (Net)	2700.79	2990.60	10381.31
2.	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extra ordinary items)	-112.00	50.69	151.04
3.	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	-113.92	19.46	100.60
4.	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	-113.92	19.46	100.60
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	329.00	329	329
6.	Equity share capital (Face value Rs. 10/- each) as shown in the Audited Balance Sheet of the previous year	950.67	836.94	950.67
7.	Earnings per share (Rs. 10/- each) (for continuing and discontinued operations)	-3.46	0.59	3.06
a) Basic		-3.46	0.59	3.06
b) Diluted		-3.46	0.59	3.06

1. The above is an extract of the detailed format of quarterly/annual financial results filed with the stock exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the quarterly & year to date financial results are available on the Stock Exchange website (www.msei.in) and the company's website (www.parijatpapermills.com).
2. The above results were reviewed by an Audit Committee and approved by the Board of Directors at its meeting held on 29.05.2024.

For and on behalf of Parijat Paper Mills Limited

 Sd/-
Amit Mittal
Whole Time Director
DIN:00754471

Date: 29.05.2024

Place: Muzaffarnagar

Phase III clinical trials of dengue vaccine to be launched soon

 PIONEER NEWS SERVICE ■
NEW DELHI

The Indian Council of Medical Research (ICMR) along with the Pune-based National Institute of Virology (NIV) and other research institutes are set to launch phase-3 clinical trials of the recombinant dengue vaccine.

Apurva Chandra, Union Health Secretary, while addressing the BRICS (Brazil, Russia, India, China, and South Africa) Health Ministers' Meeting on the sidelines of the 77th World Health Assembly (WHA) of the World Health Organization (WHO) in Geneva also informed that the BRICS Vaccine Research and Development Centre was virtually launched during India's presidency in March 2022.

"India has demonstrated active engagement in BRICS health track initiatives, promoting collaborative endeavours to advance joint health agendas aimed at fortifying health systems across BRICS nations, thereby addressing critical global health challenges," Chandra said.

"ICMR along with NIV and a network of other partner Institutes is embarking on phase-3 clinical trials of recombinant dengue vaccine."

"In addition, ICMR and other partners will also work towards research and trials for locally endemic diseases such as Kýasan Forest Disease (KFD), Nipah

virus, Human Papillomavirus, MTB-VAC (Mycobacterium Tuberculosis Vaccine), and influenza," he added.

Further, Chandra noted that India's national action plan on AMR, launched in 2017, is in line with the objectives outlined in the WHO's Global Action Plan on Antimicrobial Resistance (AMR).

"India recognises AMR as a global concern and advocates fostering collaboration among BRICS nations to devise and execute protocols, projects, and platforms to tackle AMR," the Union Health Secretary said.

He noted that "India acknowledges the importance of advancing collaboration with BRICS countries in nuclear medicine and radio-pharmaceutical science".

The country also aims to strengthen the "radio-pharmaceutical supply chain and enhance isotopes production, along with fostering the development and commercialisation of advanced digital solutions," he added.

Chandra urged member states to enhance collaboration and work together to find solutions to various health challenges.

MoU signed to boost innovation, research in medical devices for soldiers

 PIONEER NEWS SERVICE ■
NEW DELHI

The Armed Forces Medical Services (AFMS) have signed a Memorandum of Understanding (MoU) with the Indian Institute of Technology (IIT) Hyderabad to collaborate on research and training. The MoU was signed by Director General of Armed Forces Medical Services Lt General Daljit Singh, and Director of IIT Hyderabad Professor B S Murty, Defence Ministry said here on Thursday.

The MoU aims to foster innovation and research in developing novel medical devices and addressing health issues specific to soldiers serving in varied terrains. IIT Hyderabad, with its departments of Biotechnology, Biomedical Engineering, and Bioinformatics, will provide the necessary technical expertise to tackle the diverse medical challenges faced by the Armed Forces.

Professor B S Murty expressed IIT Hyderabad's dedication to addressing the problem statements presented by the Armed Forces, ensuring prompt and effective solutions to the challenges they face.

This collaboration marks a significant milestone in leveraging advanced technology and research to enhance the health and well-being of military personnel.



